Avidity Partners Management LP Portfolio Holdings

Avidity Partners Management LP

  • $370 Million
  • Q2 2025

Avidity Partners Management LP has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $370 Million distributed in 56 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Boston Scientific Corp with a value of $34.6M, Natera, Inc. with a value of $33.7M, Exact Sciences Corp with a value of $18.9M, Tenet Healthcare Corp with a value of $18.7M, and Dexcom Inc with a value of $18.4M.

Examining the 13F form we can see an decrease of $74.6M in the current position value, from $445M to 370M.

Avidity Partners Management LP is based out at Dallas, TX

Below you can find more details about Avidity Partners Management LP portfolio as well as his latest detailed transactions.

Portfolio value $370 Million
Healthcare: $370 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$147B
$34.6 Million 9.33% of portfolio
321,800
Q2 2025 Reduced 4.23%
$15.5B
$33.7 Million 9.09% of portfolio
199,300
Q2 2025 Added 67.2%
$7.33B
$18.9 Million 5.09% of portfolio
355,000
Q2 2025 Added 0.57%
$18.4B
$18.7 Million 5.04% of portfolio
106,000
Q2 2025 Added 47.22%
$31B
$18.4 Million 4.96% of portfolio
210,500
Q2 2025 Added 16.94%
$150B
$17.7 Million 4.79% of portfolio
89,700
Q2 2025 Added 101.57%
$169B
$14.7 Million 3.98% of portfolio
27,100
Q2 2025 New
$14.4B
$13.4 Million 3.63% of portfolio
650,000
Q2 2025 New
$6.74B
$13.2 Million 3.58% of portfolio
106,500
Q2 2025 New
$187B
$12 Million 3.24% of portfolio
29,600
Q2 2025 Added 90.97%
$18.4B
$11.6 Million 3.12% of portfolio
689,500
Q2 2025 Added 43.35%
$407M
$10.2 Million 2.76% of portfolio
1,064,500
Q2 2025 Added 33.06%
$245B
$9.98 Million 2.7% of portfolio
32,000
Q2 2025 Reduced 36.63%
$94.7B
$9.89 Million 2.67% of portfolio
13,500
Q2 2025 New
$4.51B
$9.86 Million 2.66% of portfolio
94,500
Q2 2025 Added 22.73%
$7.83B
$9.64 Million 2.6% of portfolio
92,000
Q2 2025 Added 17.95%
$3.09B
$8.41 Million 2.27% of portfolio
228,600
Q2 2025 Added 7.32%
$2.23B
$7.15 Million 1.93% of portfolio
134,000
Q2 2025 Added 135.09%
$1.19B
$6.96 Million 1.88% of portfolio
409,400
Q2 2025 Reduced 42.3%
$34.8B
$6.75 Million 1.82% of portfolio
27,600
Q2 2025 Reduced 65.93%
$2.3B
$6.2 Million 1.67% of portfolio
640,000
Q2 2025 Added 19.63%
$38.4B
$6.07 Million 1.64% of portfolio
32,800
Q2 2025 Reduced 16.54%
$7.28B
$6.05 Million 1.63% of portfolio
140,000
Q2 2025 Added 86.67%
$16.5B
$5.94 Million 1.6% of portfolio
59,000
Q2 2025 Reduced 44.86%
$6.14B
$5.75 Million 1.55% of portfolio
19,000
Q2 2025 New
$1.97B
$5.6 Million 1.51% of portfolio
154,000
Q2 2025 Reduced 52.19%
$10.9M
$4.93 Million 1.33% of portfolio
7,477,255
Q2 2025 Added 0.0%
$26M
$3.93 Million 1.06% of portfolio
5,615,811
Q2 2025 Added 26.07%
$887M
$3.76 Million 1.01% of portfolio
268,000
Q2 2025 New
$6.83B
$3.68 Million 0.99% of portfolio
60,000
Q2 2025 Reduced 51.02%
$2.24B
$3.38 Million 0.91% of portfolio
107,891
Q2 2025 Reduced 52.89%
$6.41B
$3.2 Million 0.86% of portfolio
33,800
Q2 2025 New
$668M
$2.89 Million 0.78% of portfolio
207,000
Q2 2025 Reduced 38.43%
$38.3B
$2.52 Million 0.68% of portfolio
15,000
Q2 2025 New
$825M
$2.18 Million 0.59% of portfolio
232,000
Q2 2025 New
$2.04B
$1.84 Million 0.5% of portfolio
39,000
Q2 2025 New
$361M
$1.79 Million 0.48% of portfolio
243,162
Q2 2025 Reduced 41.15%
$734M
$1.41 Million 0.38% of portfolio
150,000
Q2 2025 Reduced 83.78%
$28.1M
$823,000 0.22% of portfolio
1,228,910
Q4 2024 Reduced 15.17%
$177M
$406,000 0.11% of portfolio
105,000
Q2 2025 New
$9.2M
$52,000 0.01% of portfolio
138,000
Q1 2025 New
Perspective Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 15.41%
Dianthus Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 1.28%
Hinge Health Inc
-
$0 0.0% of portfolio
-
Q2 2025 New
Cg Oncology Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 52.91%
Jade Biosciences Inc
-
$0 0.0% of portfolio
-
Q2 2025 New
Apogee Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 New
Karyopharm Therapeutics Inc
-
$0 0.0% of portfolio
-
Q1 2025 New
Kezar Life Sciences Inc
-
$0 0.0% of portfolio
-
Q4 2024 New

Summary

  • Portfolio
  • No. of Stocks 56
  • Current Value $370 Million
  • Prior Value $445 Million
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 17 stocks
  • Additional Purchases 18 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 13 stocks
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email